1. Home
  2. KTB vs AKRO Comparison

KTB vs AKRO Comparison

Compare KTB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kontoor Brands Inc.

KTB

Kontoor Brands Inc.

HOLD

Current Price

$76.25

Market Cap

4.2B

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.54

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTB
AKRO
Founded
2018
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KTB
AKRO
Price
$76.25
$54.54
Analyst Decision
Strong Buy
Buy
Analyst Count
8
10
Target Price
$96.38
$73.56
AVG Volume (30 Days)
550.9K
1.7M
Earning Date
11-03-2025
11-07-2025
Dividend Yield
2.78%
N/A
EPS Growth
N/A
N/A
EPS
3.88
N/A
Revenue
$2,833,659,000.00
N/A
Revenue This Year
$20.46
N/A
Revenue Next Year
$11.11
N/A
P/E Ratio
$19.64
N/A
Revenue Growth
9.91
N/A
52 Week Low
$50.00
$21.34
52 Week High
$96.80
$58.40

Technical Indicators

Market Signals
Indicator
KTB
AKRO
Relative Strength Index (RSI) 53.32 66.54
Support Level $71.85 $54.22
Resistance Level $78.28 $54.70
Average True Range (ATR) 2.34 0.14
MACD 0.89 -0.11
Stochastic Oscillator 78.58 64.18

Price Performance

Historical Comparison
KTB
AKRO

About KTB Kontoor Brands Inc.

Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: